Reinduction therapies, stem cell transplantations, treatment-related deaths, relapse, and survival for 75 patients* with relapsed BL/B-AL between 2001 and 2016
Reinduction . | CC/AA-based . | R-ICE . | R-ICI/ICN . | VICI/ICIT . | EPOCH . | Other . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Patients | 27 | 10 | 6 | 15 | 4 | 11 | ||||||
Rituximab | 16 (/25) | 10 | 6 | 15 | 4 | 9 | ||||||
TRD before SCT | 0 | 0 | 0 | 1 | 0 | 0 | ||||||
Progression before SCT | 13 | 6 | 3 | 3 | 2 | 8 | ||||||
SCT | 20* | 6* | 3 | 11 | 2 | 4 | ||||||
Kind of SCT | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo |
12† | 8† | 4 | 2† | 1 | 2 | 0 | 11 | 0 | 2 | 3 | 1 | |
TRD after SCT | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | ||
Relapse after SCT | 8 | 3 | 2 | 2 | 1 | 1 | 1 | 0 | 2 | 1 | ||
Survival | 2 | 4* | 2‡ | 0 | 0 | 1 | 10 | 1 | 1 | 0 |
Reinduction . | CC/AA-based . | R-ICE . | R-ICI/ICN . | VICI/ICIT . | EPOCH . | Other . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Patients | 27 | 10 | 6 | 15 | 4 | 11 | ||||||
Rituximab | 16 (/25) | 10 | 6 | 15 | 4 | 9 | ||||||
TRD before SCT | 0 | 0 | 0 | 1 | 0 | 0 | ||||||
Progression before SCT | 13 | 6 | 3 | 3 | 2 | 8 | ||||||
SCT | 20* | 6* | 3 | 11 | 2 | 4 | ||||||
Kind of SCT | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo | Auto | Allo |
12† | 8† | 4 | 2† | 1 | 2 | 0 | 11 | 0 | 2 | 3 | 1 | |
TRD after SCT | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | ||
Relapse after SCT | 8 | 3 | 2 | 2 | 1 | 1 | 1 | 0 | 2 | 1 | ||
Survival | 2 | 4* | 2‡ | 0 | 0 | 1 | 10 | 1 | 1 | 0 |
allo, allogeneic SCT; auto, autologous SCT; CR, complete remission; TRD, treatment-related death.
Exclusion: 1 patient without data on treatment, 1 patient who died immediately at relapse, 2 patients who received palliative care.
SCT after second relapse/progression during reinduction: CC: 3 patients (2× auto - death of disease, 1× allo - CR), ICE: 2 patients (2× allo - death of disease).
One patient: isolated testicular relapse.